Immunotherapy meets Lung Cancer: New treatments for

Immunotherapy meets Lung Cancer:
New treatments for non small cell lung cancer and 3rd International cancer vaccine
meeting
Siena , April, 8-10 , 2016
Borgo San Luigi, Monteriggioni, Siena , Italy
Id provider: 363 Ble Consulting srl
Evento n: 151578, edizione 1
Responsabile scientifico: Dr. Pierpaolo Correale – Prof. Antonio Giordano – Prof. Luigi
Pirtoli
Destinatari: Farmacista: farmacia ospedaliera; farmacia territoriale; Biologo; Medico Chirurgo:
ematologia; genetica medica; malattie infettive; medicina interna; oncologia; radioterapia;
cardiochirurgia; chirurgia generale; chirurgia toracica; anatomia patologica; anestesia e
rianimazione; biochimica clinica; farmacologia e tossicologia clinica; laboratorio di genetica
medica; medicina nucleare; microbiologia e virologia; patologia clinica (laboratorio di analisi
chimico-cliniche e microbiologia); radiodiagnostica; medicina generale (medici di
famiglia);Chimico: Chimica Analitica
Obiettivi formativi e area formativa: linee guida - protocolli - procedure
Orario di inizio e di fine: giorno 08 aprile 2016 ore 9.00 – giorno 10 aprile 2016 ore
11.00
Numero dei crediti assegnati : 13,5
Programma dei lavori
April, 8th Day 1
9:00 – 10.00 Authority salutation
I- Standard treatment
Chairman: Prof. Luigi Pirtoli,
10:00-10:20 - Real entity of the problem; Incidence, diagnosis, staging. (L. Volterrani, Si)
10.20-10:40 - Importance of Multidisciplinary and taking in care. (A. Santo, Vr)
10:40-11.00 - The Role of Surgery. (G. Gotti, Si)
Coffe break: 11.00-11:10
11:10-11:30 - The role of Radiotherapy (P.Tini, Si)
11:30-11:50 - Prevention and treatment of infections in patients undergoing immunosuppressive
Therapy. (De Luca Si)
11.50 – 12.10 The approach to Small Cell Lung Cancer In the 21st Century (C. Pietanza,
NY,USA)
11:50-12.10 - Small cell lung and neuro-endocrine cancer: (R Addeo, Na)
12:10-12:40 - Is there still a role for chemotherapy in advanced NSCLC? (A. Rossi, Av)
12.40-13:00 - Anti-angiogenic treatments in advanced NSCLC. (V. Barbieri, CZ)
13:00-13.30 -Immunotherapy finally meets NSCLC. (P.Tagliaferri, CZ)
Lunch : 13.30- 15:00
II- Evolution of Target therapy
Chairmen: Dr. Cesare Gridelli, Prof. Antonio Giordano
15:00-15.20- Liquid biopsy development, a critical role for mNSCLC treatment (A. Russo, Pa)
15:20- 15:40- Critical role of the molecular pathologist. (C. Bellan, Si)
15:40-16:00- miRNAs and Non coding RNAs as new diagnostic and prognosis markers in NSCLC.
(M. Caraglia, Na)
16:30-17:00 - Inhibition of Alk/EML pathway. (C. Gridelli, Av)
17:00-17:30 - New target pathways. (P. Correale , SI)
17:30-18:00- from genomic to patient care. (A. Giordano, Si)
18:00-19:00 Conclusion of the day
C Gridelli, A.Rossi, P.Tagliaferri, P.Correale, L.Volterrani, A.Giordano, L.Pirtoli, C Bellan
19:00 Conclusion on the works
April,9th
Day 2 Third International cancer vaccine meeting
I- Immunotherapy and cancer
Chairmen: Sonia Quaratino and Pierosandro Tagliaferri
8.30- 9:00 History of Immunotherapy a lesson never learned (P.Tagliaferri, CZ)
9:00-9:30 Future prospectives in cancer immunotherapy (S. Quaratino, Novartis, Global)
10:00-10:30 Development for peptide cancer vaccine, lesson from clinical trial, and possibility for
the combination with immune check point inhibitors (T.Tsunoda, USA)
10:30-10:40 Coffee break
II- Immunotherapy in combination
Chairmen: Pierpaolo Correale and Kostas Kosmatopoulos
10:40-11:00 Optimized cryptic tumor antigens: neo-antigen-like cancer vaccines with broad
Application. (K Kosmatopoulos, France)
11:00-11:20 Active-specific immunotherapy aimed to thymidylate synthase inhibition. (P.Correale,
Si)
11:20-11:40 Exploring the Synergy of Combination Immunotherapy Strategies. (J.Gulley,USA)
11:40-12:00 Preclinical rationale to combine advanced radiotherapy and immunotherapy (A.Helm
Darmstadt, Germany)
III- Immunotherapy and Immune-modulation
Chairmen: Prof Michail Sitkowsky and Dr. Jay Bezofsky
12.00-12:30 Conceptually novel anti-hypoxia-A2-adenosinergic co-adjuvants to enable effective
cancer vaccines, adoptive cell transfer, and blockade of CTLA4/PD1 (M.Sitkovsky, USA)
12:30-13:00 Stress, Death, Immunity and Cancer Therapy (L Galluzzi, France)
13:00-13:30 Cancer vaccine strategies (J.Berzofsky,USA)
13:30-15:00 lunch
IV Experimental models
Chairmen: Enzo Bonmassar and Jack Greiner
15:00-15:30 The generation and analysis of a novel combination of recombinant adenovirus
vaccines targeting three tumor antigens as an immunotherapeutic. (K. Y Tsang, USA)
15:30-16:00 Preclinical Studies Combining Cancer Vaccines with T cell Checkpoint Inhibitors. (J.
Greiner, USA)
16:00-16:20 Immunotherapy Principles and Combinations Investigated in the treatment of Prostate
Cancer ( A Madan Ravi, USA)
16:20-16:40 Omics-based approaches in cancer immunology: the next frontier of translational
oncology (C. Botta, CZ)
16:40-17:00 Integrating Genomics and Immunology toward Precision Immunotherapy in Lung
Cancer (T. Franchina, Me)
17:20-17:40 Do we need dendritic cell for the new generation of immunotherapy strategies? (M.
Nuti, Rm)
17:40- 18:00 Cancer Immunotherapy: Chemical xenogenization and immune checkpoint inhibitors.
(Enzo Bonmassar, Rm)
IV Antibodies involvement in cancer immunology
Chairmen: Philip Arlen and Vincenzo Adamo
18.00- 18:15 Design and Development of immunogenic Mabs targeting novel tumor specific
antigens. (P. Arlen, USA)
18:15-18:30 Discovery and development of a novel monoclonal antibody, NEO-201, targeting solid
tumors (C.M. Annunziata, USA)
18:30-18:40 Immunological effects of Cetuximab in colon cancer patients a new modality in a old
strategy. (EC Martino, Si)
18:40-18:50 Immunomodulating effects of anti-VEGF mAbs. (F.Vanni, Si)
18:50-19:50 Round Table: anticancer immunotherapy: current results, trial
Interpretations and realistic expectation
Berzofsky, Sitkovsky, Tagliaferri, Tsang, Gulley, Nuti, Bonmassar, Greiner, Correale
20:00 conclusion of the works
April 10th 2016 Day 3 V
New treatments for non small cell lung cancer and III International cancer vaccine
meeting
09:00 Conclusion of the works and Selected oral communications
Chairmen: Pierosandro Tagliaferri and Michele Caraglia
Time 9-10 (5 minute presentations)
11.00 Chairs’ Conclusion of the day and questionnaire ecm
Razionale
Immunotherapy meets Lung Cancer:
New treatments for non small cell lung cancer and 3rd International cancer vaccine meeting
Non small cell lung cancer is the most common malignant disease worldwide and often is
accompanied by concomitant diseases and severe complications. The prognosis of those patients
who cannot undergo radical surgery is poor, with a survival that barely is longer than 12 months.
New treatments are however, continuously entering in the clinical practice of these patients,
including small molecules with specific molecular targets and immunotherapy. The correct use of
these new drugs and biological agents therefore, requires the knowledge of molecular biology,
antitumor immunology, new diagnostic techniques and pathology. Often their prescription needs
multiple and complex interdisciplinary interactions. This meeting offers the possibility to understand
the new modalities of treatment and care of lung cancer patients, to promote interdisciplinary
interactions, and to define the mechanisms of action and the rationale behind of the use of the
most recent drugs. The combined meeting finally, will attempt to make a light on the development
of immunotherapy strategies in the treatment of these patients and to track a new way for the
design of new therapeutic combination strategies.
Acronimi
NSCLC : Non Small Cell Lunch Cancer
mNSCLC: micro Non Small Cell Lunch Cancer
miRNAs: micro Ribonucleic acid
RNAs : Ribonucleic acid
Alk/EML: anaplastic lymphoma kinase - Echinoderm microtubule-associated protein - like
CTLA4/PD1: Cytotoxic T-Lymphocyte Antigen 4) - Programmed cell Death 1)
Mabs: multi agent based simulation
NEO-201 Neogenix Oncology
VEGF mAbs: Vascular endothelial growth factor - multi agent based simulation
Curriculum Vitae
Christina Messineo Annunziata, M.D., Ph.D.
Current Address:
National Cancer Institute
Center for Cancer Research
Women’s Malignancies Branch
Building 10, Room 4B-56
10 Center Drive
Bethesda, Maryland 20892
Tel: (301) 402-7189
Fax: (301) 480-6255
Email: annunzic@mail.nih.gov
Education:
1992
2000
2000
Bachelor of Science, magna cum laude, Biology Georgetown
University College of Arts and Sciences 3700 O Street, NW
Washington, D.C. 20057
Doctor of Philosophy, Department of Pathology, Georgetown
University College of Arts and Sciences 3700 O Street, NW
Washington, D.C. 20057
Doctor of Medicine Georgetown University School of Medicine 3900
Reservoir Road, NW Washington, D.C. 20057
Training/Employment/Experience:
1990-1992
Research Assistant, Laboratory of Diane W. Taylor, Ph.D.,
Department of Biology Georgetown University College of Arts and
Sciences 3700 O Street, NW Washington, D.C. 20057
1994-1998
Pre-doctoral Candidate, Laboratory of Jeffrey Cossman, M.D.,
Department of Pathology Georgetown University School of Medicine
3900 Reservoir Road, NW Washington, D.C. 20057
2000-2002
Resident, Department of Internal Medicine Georgetown University
School of Medicine 3900 Reservoir Road, NW Washington, D.C.
20057
2002-2006
Medical Oncology Fellow, Medical Oncology Branch, NCI
Building 10, Room 12N226 - 10 Center Drive Bethesda, MD 208921906
2003-2007
Research Fellow, Laboratory of Louis M. Staudt, M.D., Ph.D.,
Metabolism Branch, National Cancer Institute Building 10, Room
4N113 10 Center Drive Bethesda, MD 20892
2005-2007
Clinical Fellow, Medical Ovarian Cancer Clinic, Medical Oncology
Branch, National Cancer Institute Building 10, Room 12N226
10 Center Drive Bethesda, MD 20892-1906
2007-2010
Associate Clinical Investigator, Medical Oncology Branch, NCI
Building 10, Room 12N226 10 Center Drive Bethesda, MD 208921906
2010-2013
Investigator, Medical Oncology Branch, National Cancer Institute
Building 10, Room 12N226 10 Center Drive Bethesda, MD 208921906
Investigator, Women’s Malignancies Branch, National Cancer
Institute Building 10, Room 4B-56 10 Center Drive Bethesda, MD
20892
2013-present
Board Certifications, Licenses:
2001
United States Medical Licensing Exam Washington, D.C. Medical
License
Board Certification, Internal Medicine, American Board of Internal
Medicine
2003
2006
Board Certification, Medical Oncology, American Board of Internal
Medicine
CURRICULUM VITAE
Name: Philip M. Arlen, M.D.
Citizenship:
United States
Education:
1986
B.A. Emory University, Atlanta, Georgia
1991
M.D. Medical College of Georgia, School of Medicine, Augusta, Georgia
Brief Chronology of Employment:
1991 – 1992
Internship, Internal Medicine, Georgia Baptist Medical Center, Atlanta, GA
1992 – 1994
1994 – 1997
1997 – 1999
Residency, Internal Medicine, Georgia Baptist Medical Center, Atlanta, GA
Fellowship, Hematology/Oncology, Emory University, Atlanta, GA
Fellowship, Biotechnology Fellow, Laboratory of Tumor Immunology and
Biology, Division of Basic Sciences, National Cancer Institute, NIH,
Bethesda, MD
1998 – Present
Attending Physician, Medical Oncology, Watler Reed National Military
Medical Center/National Cancer Institute, NIH, Bethesda, MD
1999 – Present
Attending Physician, Prostate Cancer Clinic, Warren Grant Magnuson Clinical
Center, National Cancer Institute, Medical Oncology Branch, NIH, Bethesda,
MD
1999 – Present
Senior Medical Staff, Warren Grant Magnuson Clinical Center, National
Cancer Institute, Medical Oncology Branch, NIH, Bethesda, MD
1999 – 2001
Clinical Special Expert, Laboratory of Tumor Immunology and Biology,
Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD
2001 – 2003
Co-Director, Clinical Trials Group, Laboratory of Tumor Immunology and
Biology, Center for Cancer Research, National Cancer Institute, NIH,
Bethesda, MD
2001 – 2005
Staff Clinician, Laboratory of Tumor Immunology and Biology, Center for
Cancer Research, National Cancer Institute, NIH, Bethesda, MD
Brief Chronology of Employment (continued):
2004 – 2008
2006 – 2008
2007 - 2008
2008 – 2012
2010 – 2012
2008 – present
2012 – present
Director, Clinical Research Group, Laboratory of Tumor Immunology and
Biology, Center for Cancer Research, National Cancer Institute, NIH,
Bethesda MD
Senior Clinician, Laboratory of Tumor Immunology and Biology, Center for
Cancer Research, National Cancer Institute, NIH, Bethesda, MD
Adjunct Investigator, Medical Oncology Branch, Center for Cancer
Research, National Cancer Institute
President, Chief Medical Officer, Neogenix Oncology Inc., Rockville, MD
Chief Executive Officer, Neogenix Oncology, Inc., Rockville, MD
Special Volunteer-Senior Clinical Staff, Medical Oncology Branch, Center
for Cancer Research, National Cancer Institute
President & Chief Executive Officer, Precision Biologics, inc., Rockville,
MD
Active State Medical Licenses:
Maryland, license # D55489
1998 - Present
Georgia, license # 036052
1992 - Present
DEA # BA3373141
1992 - Present
Board Status/Certifications:
Certified as a Diplomate in Medical Oncology - American Board of Internal Medicine Basic Life
Support
NCI Intramural Committees:
Member, Center for Cancer Research (CCR) Advisory Board (CAB), NCI, NIH
*Member, Breast Cancer Faculty, NCI, NIH
Member, Genitourinary Malignancies Faculty, NCI, NIH
Member, Vaccine Working Group, NCI, NIH
Member, Gastrointestinal Malignancies Faculty, NCI, NIH
*Steering Committee- 2003-2008
CURRICULUM VITAE
January 10, 2016
Name: Jay Arthur Berzofsky
Marital Status: Married; two children
Education:
1967 - A.B., Harvard University (Summa Cum Laude in Chemistry)
1971 - Ph.D., Albert Einstein College of Medicine, Molecular Biology
1973 - M.D., Albert Einstein College of Medicine, Medical Scientist Training Program
Brief Chronology of Employment:
1973 - 1974
Medical Internship (Straight Medicine), Massachusetts
General Hospital, Boston, Massachusetts
1974 - 1976
Research Associateship, Laboratory of Chemical Biology
National Institute of Arthritis, Metabolism, and
Digestive Diseases, National Institutes of Health
1976 - 1979
Investigator ("Expert"), Metabolism Branch, National
Cancer Institute, National Institutes of Health
1979 - 1987
Senior Investigator, Metabolism Branch, National
Cancer Institute, National Institutes of Health
1987 - 2003
Chief, Molecular Immunogenetics and Vaccine Research
Section, Metabolism Branch, National Cancer Institute,
2004 – Date
National Institutes of Health
Chief, Vaccine Branch, Center for Cancer Research,
National Cancer Institute, National Institutes of Health
Other Research Experience:
Summers,1962 - 1965 Research Assistant, Pediatric Research Unit (H. M. Nitowsky), Sinai Hospital,
Baltimore, Maryland Summer, 1966
Research Assistant, Organic Synthesis Laboratory C. H. Robinson),
Department of Pharmacology, Johns Hopkins School of Medicine, Baltimore, Maryland Summer, 1967
Visiting Scientist, Laboratoire d'Enzymologie (G. N. Cohen), Centre National de la Recherche
Scientifique, Gif-sur-Yvette, France
Medical Licensure:
Maryland and Massachusetts
Major Outside Activities (Not permitted by NIH after 2005)
Medimmune, Inc.—Scientific Founder and Chair, Scientific Advisory Board, 1989-2002
Magainin Pharmaceuticals, Inc.—Member, Scientific Advisory Board, 1991-97 Diacrin, Inc.—Member,
Scientific Advisory Board, 1993-2002 Pharmadyne, Inc.—Scientific Co-Founder and Chair, Scientific
Advisory Board, 1997-2004 Boston University Community Technology Fund—Consultant, 1997-1999
Health Care Ventures, Inc.—consultant, 1998 EMD Pharmaceuticals, Inc.—consultant, 2000-2003 Epivax,
Inc.—Member, Scientific Advisory Board, 2000-2004 Therapeutic Devices, Inc.—consultant, 2002-2004
Transform Pharmaceuticals, Inc.—consultant 2002-2005 Celera Genomics, Inc.—consultant 2002-2004
Genencor International, Inc.—consultant 2003-2004.
Major areas of research:
1. Molecular basis of antigen recognition by T lymphocytes
2. Processing of antigens and their presentation by major
histocompatibility molecules
3. Structure of antigenic sites on protein antigens
4. Genetic regulation of the immune response
5. Design and development of artificial vaccines based on
immunological principles and peptide synthesis or
recombinant DNA technology
6. AIDS vaccines and diagnostic techniques
7. Malaria vaccines
8. Cancer vaccines
9. Antigen-antibody interactions
10. Structure-function relationships in proteins and protein
conformation.
11. Regulation of tumor immunosurveillance and T cell
function by cytokines and regulatory cells
12. NKT cells in the regulation of tumor immunity
13. Mucosal immunity and vaccines
14. Cytokines, chemokines, and TLR ligands as immune
modulators and vaccine adjuvants.
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FIVE PAGES.
NAME:
Sitkovsky, Michail Vladimirovich
Director, New England Inflammation and Tissue Protection Institute
Presidential Scholar, Cancer Vaccine Center,
Dana-Farber Cancer Institute, Harvard Institutes of Medicine
eRA COMMONS USER NAME (credential, e.g., agency login): MISHA1
POSITION TITLE:
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training
and residency training if applicable. Add/delete rows as necessary.)
DEGREE
Completion Date
FIELD OF STUDY
INSTITUTION AND LOCATION
(if applicable)
MM/YYYY
Moscow State University, USSR
M.S.
1970
Biophysics &
Physiology
DEGREE
(if applicable)
INSTITUTION AND LOCATION
Completion Date
MM/YYYY
FIELD OF STUDY
Moscow State University, USSR
Ph.D
1973
Biochemistry
Massachusetts Institute of Technology, Boston
Post Doc
1981- 1984
Immunology
A. Personal Statement
I am the Founder and President of RedoxTherapies, Inc. (Redox) that is advancing the conceptually novel
treatment of cancer based on technology that I created while a Lab Chief in intramural NIAID/NIH
(1984-2004) for the conceptually novel use and re-purposing of the synthetic A2A adenosine
receptor (A2AR) antagonists, including V2006. This technology and Method-of-use Patent is
licensed to Redox by NIH with a charge to translate it into cancer therapies.
I believe that Redox is a good choice to collaborate with NCI in the clinical development of A2AR antagonist
V2006. Redox is well-suited to orchestrate the clinical solution of the elusive complex problem of improving
tumor rejection by immunotherapies and standard-of -are chemotherapies of cancer.
This is because my lifelong work (1974-present) to study the immunogenic and poorly-immunogenic
tumors resulted in the discovery of the major “hypoxia-A2A-adenosinergic” tumor-protecting mechanism
and the A2A adenosine receptor targeting treatments to overcome tumor’s defense.
My team is credited with uncovering that it is the tumor’s hypoxia-driven generation of extracellular
adenosine, which then signals through tissue-protecting immunosuppressive A2AR to inhibit incoming antitumor T and Natural Killer cells (Nature, 2001; PNAS, 2006).
This understanding led us to introduce several new types of anti-cancer drugs that work by re-programing
the tumor microenvironment (TME) away from tumor-protection and toward tumor-suppression. We call
these drugs “anti-hypoxia-A2A-adenosinergic co-adjuvants” because they enhance immune response by
preventing the constitutive inhibition of the immune response. Fortuitously, these drugs are already
available since they were developed for other diseases and this proposal is designed to accelerate their repurposing for cancer vaccines as the most immediate application. As a “bonus” these drugs also weaken all
other known biochemical (Cox-2) and immunological tumor-protecting mechanisms (e.g. CTLA-4/PD1).
We also recently published the conceptually novel medical use of anti-hypoxic respiratory hyperoxia (i.e.
breathing 60% oxygen) to lower the levels of adenosine in the TME, inhibit tumor protection, and make
tumors vulnerable to immunotherapies of cancer especially if this will combined with V2006. This will
further improve the clinical efficacy of V2006.
I am perfectly prepared for this collaboration with NCI because of my background and my past and ongoing
experience in administering Redox, my Institute, my appointment in Dana Farber Cancer Institute at
Harvard my and my scientific projects. I know how to have effectively communicate with others and to
develop a realistic plan, timeline, and budget. Redox has all that is needed to succeed in this collaboration
with NCI, including the unique insights, supportive and enthusiastic clinician scientists and the necessary
expertise
DOTT. CESARE GRIDELLI: CURRICULUM VITAE
Data di Nascita:
Luogo di nascita:
Laurea in Medicina e Chirurgia:
Abilitazione Medica:
Esperienza:
24 -3 - 1961
Napoli
30 - 7 - 1985
110/110 e lode
Facoltà di Medicina e Chirurgia, Università "Federico II" di Napoli
26 - 2 - 1986
Università di Napoli
1983 - 1985
Allievo Interno,
Cattedra di Oncologia Medica, Fac. di Med. e Chir., Univ. "Federico II" di Napoli
1985 - 1988
Specializzando,
Cattedra di Oncologia Medica, Fac. di Med. e Chir., Univ. "Federico II" di Napoli
1988 - 1993
Medico Interno,
Cattedra di Oncologia Medica, Fac. di Med. e Chir., Univ. "Federico II" di Napoli
Dicembre 1993
Assistente,
Divisione di Oncologia Medica B, Istituto Nazionale Tumori, Napoli
Specializzazione in Oncologia:
Specializzazione in Medicina Interna:
Attività di insegnamento
Interessi di Ricerca:
Appartenenza a Società Scientifiche:
Revisore ECM
Dicembre 1995
Dirigente di I° Livello
Divisione di Oncologia Medica B, Istituto Nazionale Tumori, Napoli
Gennaio 2001
Responsabile (Dirigente di Struttura Semplice a carattere dipartimentale)
Unità Operativa di Chemoterapia Ambulatoriale
Istituto Nazionale Tumori-Napoli
Posizione Attuale
Dal Dicembre 2001
Direttore di Struttura Complessa U.O. Oncologia Medica, A.O.R.N. “S.G. Moscati”,
Avellino
Dal Dicembre 2003
Direttore del Dipartimento di Onco-Ematologia, A.O.R.N. “S.G. Moscati” Avellino
12 - 7 - 1988
70/70 e lode
Facoltà di Medicina e Chirurgia, Università "Federico II" di Napoli
15 - 7 - 1993
Facoltà di Medicina e Chirurgia, Università "Federico II" di Napoli
Professore a contratto in Oncologia Medica presso la Scuola di Specializzione in
Oncologia della Università “Federico II” di Napoli dall’anno 2002.
Professore a contratto in Oncologia Medica presso la Scuola di Specializzazione in
Oncologia della Seconda Università di Napoli dall’anno 2004.
Direttore della Scuola Italiana di Oncologia Toracica (SIOT) dall’anno 2008.
Tumori del Polmone, Neoplasie nell’anziano
Associazione Italiana di Oncologia Medica (A.I.O.M.) dal 1988
Membro del Consiglio Direttivo Nazionale dal 2006 al 2007
International Association for the Study of Lung Cancer (I.A.S.L.C.) dal 2006
American Association of Clinical Oncology (A.S.C.O.) dal 1995
International Society of Geriatric Oncology (S.I.O.G.) dal 2003 al 2009
Associzione Italiana di Oncologia Toracica (AIOT), Segretario dal 2007
Euroepan Society of Medical Oncology (ESMO) dal 2008
Revisore per il Ministero della Sanità per l’EMC dal 2002
Esperto Europeo EMEA
Esperto Europeo in Oncologia per l’European Medicine Evaluation Agency (EMEA)
Londra (UK) anno 2004
Corsi di management:
Corso di management per medici dirigenti di II livello “Ippocrate” effettuato
presso la Scuola di Direzione Aziendale dell’Università “Luigi Bocconi” di
Milano. Febbraio - Marzo - Aprile 1999.
Autore di più di 700 pubblicazioni tra abstracts e lavori per estenso su riviste nazionali e internazionali (di
cui oltre 350 su riviste internazionali indexate).
Avellino, 26 Gennaio 2016
Curriculum vitae Dr. Paolo Tini
DOTT. TINI PAOLO
Cognome e nome
Luogo e data di nascita ACQUAPENDENTE - VT- 18/04/1981
Iscrizioni

02/04/2008 - Albo Provinciale dei Medici Chirurghi di VITERBO
(Ordine della Provincia di VITERBO) n. 0000002283
Lauree

10/07/2007 - MEDICINA E CHIRURGIA (SIENA)
Abilitazioni

2007 /2 - Medicina e Chirurgia (SIENA)
Radioterapia
Specializzazioni
Ag oggi ricopre attività specialistica in “Radioterapia” – attività nell’ambito della gestione dei
percorsi clinico-assistenziali e ricerca in ambito /radioterapico/radiobilogico presso l'UNITà
OPERATIVA COMPLESSA Radioterapia dell'AZIENDA OSPEDALIERA
UNIVERSITARIA SENESE
Memorial Sloan-Kettering Cancer Center and
Weill Cornell Medical College
Required Format for Curriculum vitae and Bibliography
Date of preparation:
November 15, 2015
A.
1.
2.
GENERAL INFORMATION
Name
Office address:
3.
Office telephone:
Office fax:
Home address:
Home telephone:
Cell phone:
Beeper:
Email:
Citizenship:
If not USA, do you have: N/A
(a) An immigrant visa?
(b) A non-immigrant visa?
4.
5.
6.
7.
8.
a.
b.
g.
h.
B.
1.
Optional Information:
Date of birth:
Place of birth:
Languages spoken/written:
Gender:
Maria Catherine Pietanza, MD
Memorial Sloan-Kettering Cancer Center Department
of Medicine, Thoracic Oncology Service 300 East 66th
Street
New York, NY 10065
646-888-4203
646-888-4262
422 East 72nd Street, Apartment 29B
New York, New York 10021
917-596-6044
917-596-6044
917-218-1993/2286
pietanzm@mskcc.org
USA
English, Italian, and Spanish
EDUCATIONAL BACKGROUND
Degree(s)(B.A. and above):
Degree
Institution name and location
Dates attended
Year Awarded
BA, cum laude
New York University, NY, NY
Chemistry and Italian
1991-95
1995
MD, cum laude
SUNY Health Science Center at
Brooklyn/Downstate, Brooklyn, NY
1997-2001
2001
C.
1.
PROFESSIONAL POSITIONS AND EMPLOYMENT
Post-doctoral training including residency/fellowship
Title
Institution name and location
Dates
Intern & Resident, Medicine
New York Presbyterian Hospital/Weill
Cornell Medical Center, NY, NY
2001-04
Fellow, Hematology/Oncology
Mount Sinai School of Medicine, NY, NY
2004-07
Chief Fellow,
Hematology/Oncology
Mount Sinai School of Medicine, NY, NY
2005-06
Research Fellow,
Hematology/Oncology
Mount Sinai School of Medicine, NY, NY
2006-07
2.
Academic positions (teaching and research)
Title
Institution name and location
Dates
Assistant Member, Level I
Memorial Sloan-Kettering Cancer Center
NY, NY
2007-2012
Instructor in Medicine
Weill Medical College of Cornell University
NY, NY
2007-2012
Assistant Member
Memorial Sloan-Kettering Cancer Center
NY, NY
2012-present
Assistant Professor of Medicine
Weill Medical College of Cornell University
NY, NY
2012-present
3.
Hospital positions (e.g., attending physician)
Title
Institution name and location
Dates
Assistant Attending Physician
Memorial Hospital for Cancer & Allied
Diseases, NY, NY
2007-
Title
Institution name and location
Dates
Research Assistant
The Rockefeller University
Synthetic Protein Chemistry Laboratory
NY, NY
1996-97
4.
D.
1.
Other Employment
LICENSURE, BOARD CERTIFICATION, MALPRACTICE
Licensure
a.
State
Number
Date of issue
Date of expiration
New York 231037
1/15/2004
4/30/2017
b. If no license: N/A
(1) Do you have a temporary certificate?
(2) Have you passed the examination for foreign medical school graduates?
c. DEA number: FP0257849
d. NPI number: 1639384522
2.
Board Certification
Full Name of Board
Certificate #
Date
(MM/DD/YY)
Internal Medicine
228293
08/24/2014
Medical Oncology
228293
11/13/2017
3.
Malpractice insurance
Do you have Malpractice insurance? Yes
Name of Provider: MSK Insurance US, Inc
Premiums paid by: Institution (Memorial Sloan-Kettering Cancer Center)
G.
INSTITUTIONAL/HOSPITAL AFFILIATION
Primary Hospital Affiliation:
Other Hospital Affiliations:
Other Institutional Affiliations:
H.
Memorial Hospital for Cancer and Allied Diseases
None
Weill Cornell Medical College
EMPLOYMENT STATUS
Name of Employer(s): Memorial Sloan-Kettering Cancer Center
Employment Status: Full-time salaried
TAGLIAFERRI
PIERSANDRO
Qualifica:
Professore Straordinario
Orario di ricevimento:
martedi alle ore 16.30
Luogo di ricevimento:
U.o. Oncologia livello 9 - edificio clinico A- Campus
Germaneto
Email:
Telefono:
Curriculum Scientifico:
Curriculum Didattico:
tagliaferri@unicz.it
09613694324
VISUALIZZA SCHEDA RICERCA
Il Prof. Pierosandro Tagliaferri, nato a Napoli il 20.12.1956, è
straordinario di Oncologia Medica (MED/06) dal dicembre
2006. In precedenza aveva rivestito il ruolo di professore
associato, sempre nello stesso settore disciplinare dal
novembre 1998 in questo Ateneo e ancora precedentemente
di funzionario tecnico di VIII livello presso l’Università Federico
II di Napoli. Il Prof. Tagliaferri ha svolto attività di ricerca per
un periodo complessivo di 3 anni presso il National Cancer
Institute di Bethesda, dal 1983 al 1987. Le attività di ricerca
oncologiche, concretizzate da oltre 100 pubblicazioni su
prestigiose riviste internazionali e dalla presentazione a
congressi di rilievo nazionale ed internazionale, nonché
dall’acquisizione di finanziamenti per le attività di ricerca
stesse, sono basate su un approccio di ricerca traslazionale
che integra le moderne acquisizioni molecolari e le nuove
tecnologie con i criteri metodologici della medicina basata
sull’evidenza. In particolare l’attività di ricerca in ambito preclinico e clinico si è basata sullo studio di citochine antitumorali, sull’impiego di farmaci a bersaglio molecolare,
sull’identificazione di vie di survival e su approcci per la
definizione di trattamenti antitumorali individualizzati sulle
caratteristiche bio-molecolari delle neoplasie.
Nome
Indirizzo
Telefono
Fax
E-mail
Nazionalità
Data di nascita
MICHELE CARAGLIA
VICO I DENTICE, 8 83031 ARIANO IRPINO (AV)
0815665871
0815665863
Michele.caraglia@unina2.it
Italiana
18/04/1966
ESPERIENZA LAVORATIVA
• Date (da – a)
• Nome e indirizzo del datore di
lavoro
• Tipo di azienda o settore
• Tipo di impiego
• Principali mansioni e
responsabilità
• Date (da – a)
• Nome e indirizzo del datore di
lavoro
• Tipo di azienda o settore
• Tipo di impiego
• Principali mansioni e
responsabilità
1 Novembre 2011–ad oggi
Dipartimento di Biochimica e Biofisica- Seconda Università di Napoli- Via
Costantinopoli 16 80138 Napoli
Seconda Università di Napoli: Ricerca e formazione universitaria di studenti afferenti
alla facoltà di medicina.
Professore Associato in Biochimica
Responsabile del Laboratorio di Trasduzione del Segnale: gestione di diversi progetti
di ricerca in collaborazione con aziende farmaceutiche interessate allo sviluppo di
farmaci anti-tumorali quali la Novartis-Oncology; gestione di progetti di ricerca
finanziati dalla Regione Campania e finalizzati allo sviluppo di un Laboratorio Pubblico
per il trasferimento di nanotecnologie ad industrie farmaceutiche ed altre aziende
private. Insegnamento presso il corso di laurea in Informatore Medico Scientifico e
presso il corso di laurea in Biotecnologie ad indirizzo medico. Finanziamento
dall’Ateneo per un progetto di rilevante interesse di ateneo sul cancro del colon.
Responabile Nazionale PRIN 2008 dal MIUR. Responsabile progetto finanziato
dalla’AIRC per gli anni 2010-2012.
Finanziamento come coordinatore sceintifico dalla Regione Campania per Laboratori
Pubblici Hauteville di 800.000 euro. Insegnamento presso le scuole di specializzazione
in Biochimica Clinica, Microbiologia, Cardiochirugia e Chirurgia Toracica, e in
Reumatologia. Insegnamento presso il Dottorato di ricerca in Alimenti e Salute:
fisiopatologia dell’apparato gastroenterico.
3 giugno 2008-20 agosto 2010
Dipartimento di Biochimica e Biofisica- Seconda Università di Napoli- Via
Costantinopoli 16 80138 Napoli
Seconda Università di Napoli: Ricerca e formazione universitaria di studenti afferenti
alla facoltà di medicina.
Ricercatore Universitario e Professore aggregato in Biochimica Clinica e Biologie
Molecolare e Clinica
Responsabile del Laboratorio di Trasduzione del Segnale: gestione di diversi progetti
di ricerca in collaborazione con aziende farmaceutiche interessate allo sviluppo di
farmaci anti-tumorali quali la Novartis-Oncology; gestione di progetti di ricerca
finanziati dalla Regione Campania e finalizzati allo sviluppo di un Laboratorio Pubblico
per il trasferimento di nanotecnologie ad industrie farmaceutiche ed altre aziende
private. Tali progetti si svolgono nell’ambito di sviluppo di nuove strategie terapeutiche
basate sull’impiego di aminobifosfonati e di individuazione di nuovi marcatori
molecolari diagnostici e prognostici nell’adenocarcinoma prostatico. Insegnamento
presso il corso di laurea in Informatore Medico Scientifico e presso il corso di laurea in
Biotecnologie ad indirizzo medico. Finanziamento dall’Ateneo per un progetto di
rilevante interesse di ateneo sul cancro del colon. Insegnamento presso le scuole di
specializzazione in Biochimica Clinica e in Reumatologia. Insegnamento presso il
Dottorato di ricerca in Alimenti e Salute: fisiopatologia dell’apparato gastroenterico.
• Date (da – a)
• Nome e indirizzo del datore di
lavoro
• Tipo di azienda o settore
• Tipo di impiego
• Principali mansioni e
responsabilità
DAL 1.09.04 al 2.06.08
Istituto Nazionale dei Tumori- Fondazione “G. Pascale” di Napoli- Unità operativa
complessa di Farmacologia Sperimentale Oncologica- Via Mariano Semmola 1 80131
Napoli
Istituto di ricerca e cura a carattere scientifico
Dirigente Medico di I livello- Dirigente del laboratorio di Biochimica
Ha diretto il laboratorio di Biochimica sovrintendendo il lavoro di ricerca di 3 contrattisti
e 4 tesisti in Science Biologiche e Chimica e Tecnica Farmaceutica (CTF). Ha ricevuto
un finanziamento triennale dall’Associazione per la Ricerca sul Cancro ed uno
biennale dal Ministero della Salute per la ricerca nel campo dell’adenocarcinoma della
prostata finalizzata alla scoperta di nuovi marcatori molecolari di diagnosi e prognosi e
su nuove terapie sperimentali impieganti inibitori dell’isoprenilazione (aminobifosfonati
ed inibitori della farnesiltransferasi). Ha ricevuto due finanziamenti dalla Novartis
Oncology e dalla Janssen e Cilag per ricerche nello stesso settore. Ha diretto la
formazione di diversi tesisti in Scienze Biologiche, CTF, Biotecnologia e Tecnici di
Laboratorio Biomedico.
• Date (da – a)
• Nome e indirizzo del datore di
lavoro
• Tipo di azienda o settore
• Tipo di impiego
• Principali mansioni e
responsabilità
DAL 16.10.2000 al 31.08.04
Ospedale “S. Giovanni di Dio”, ASL Napoli 3 di Frattamaggiore (NA), Unità Operativa
Complessa di Oncologia- Via Pirozzi Frattaminore (NA)
Ospedale Civile
Dirigente Medico di I livello
Trattamento di pazienti affetti da metastasi cerebrali di diversa derivazione
istogenetica. Disegno di nuovi protocolli terapeutici nel trattamento medico delle
metastasi cerebrali. Trattamento di pazienti con adenocarcinoma della prostata
ormono-refrattario e del carcinoma della mammella in fase metastatica. Insegnamento
di Oncologia presso la Scuola Infermieri Professionali della Università “Federico II” di
Napoli affidati all’Ospedale “S. Giovanni di Dio” di Frattamaggiore. Collaborazione
scientifica con il Laboratorio di Biochimica diretto dal Prof. Alberto Abbruzzese presso
il Dipartimento di Biochimica e Biofisica della Seconda Università di Napoli.
• Date (da – a)
• Nome e indirizzo del datore di
lavoro
• Tipo di azienda o settore
• Tipo di impiego
• Principali mansioni e
responsabilità
DAL 1998 al 2001
Dipartimento di Biochimica e Biofisica- Seconda Università di Napoli- Via
Costantinopoli 16 80138 Napoli
Seconda Università di Napoli
Dottorato di Ricerca in Biochimica Cellulare
Dirige il Laboratorio di Biochimica del Prof. Alberto Abbruzzese. Partecipa a diversi
finanziamenti dal Ministero della Ricerca Scientifica e Tecnologica coordinati a livello
nazionale dal prof. Abbruzzese e focalizzati alla definizione di vie di fuga dall’attività
antiproliferativa di citochine come l’interferone alfa ed altri agenti anti-tumorale diretti
contro bersagli specifici come l’acido zoledronico. Ha sovrinteso alla formazione
tecnica e scientifica di almeno 4 tesisiti in Scienze Biologiche.
• Date (da – a)
• Nome e indirizzo del datore di
lavoro
• Tipo di azienda o settore
• Tipo di impiego
• Principali mansioni e
DAL 1994 al 1998
Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica dell’Università
“Federico II” di Napoli- Via S. Pansini 80131 Napoli
Università “Federico II” di Napoli
Borsista della Associazione Italiana per la Ricerca sul Cancro
Dirige ed esegue un programma di ricerca finanziato dall’AIRC presso il Laboratorio
responsabilità
diretto dal Prof. P. Tagliaferri. Tale progetto è finalizzato alla definizione di vie di fuga
in cellule derivate da tumori squamosi della testa e del collo dall’attività antiproliferativa
ed apoptosi indotte dall’interferone alfa. Ha individuato una via specifica dipendente da
ras che protegge le cellule tumorali dall’inibizione proliferativa da interferone alfa e ha
definito una nuova strategia terapeutica per il supermanto di tale meccanismo di
escape. Nel corso di tale programma ha diretto anche la formazione tecnica e
scientifica di 5 tesiste in Scienze Biologiche.
• Date (da – a)
• Nome e indirizzo del datore di
lavoro
• Tipo di azienda o settore
• Tipo di impiego
• Principali mansioni e
responsabilità
DAL 1993 al 1994
Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica dell’Università
“Federico II” di Napoli- Via S. Pansini 80131 Napoli
Università “Federico II” di Napoli
Borsista della Fondazione Angelo Marinelli di Napoli
Dirige ed esegue un programma di ricerca finanziato da tale associazione presso il
Laboratorio diretto dal Prof. P. Tagliaferri. Tale progetto è finalizzato alla definizione
degli effetti di agenti antitumorali sia citotossici convenzionali come la citosina
arabinoside e la 5Azadesossicitidina che agenti biologici come l’interferone alfa nella
regolazione dell’espressione di recettori di membrana di fattori di crescita peptidici
come il recettore per il fattore di crescita epidermico (EGF-R), il recettore per la
transferrina (TRF-R) ed il recettore per il fattore di crescita neurale (NGF-R).
ISTRUZIONE E FORMAZIONE
• Date (da – a)
• Nome e tipo di istituto di istruzione
o formazione
• Principali materie / abilità
professionali oggetto dello studio
• Qualifica conseguita
• Livello nella classificazione
nazionale (se pertinente)
Dal 13 Dicembre 1997 al 13 Dicembre 1999
Corso di Formazione della Regione Campania per Medico di Medicina Generale
• Date (da – a)
• Nome e tipo di istituto di istruzione
o formazione
• Principali materie / abilità
professionali oggetto dello studio
1990-1994
Specializzazione in Oncologia ad indirizzo medico presso la Facoltà di Medicina della
Università “Federico II” di Napoli.
Oncologia Medica; Oncologia Molecolare; Oncologia Sperimentale; Frequenza presso
il laboratorio di Biologia Cellulare diretto dal Prof. P. Tagliaferri per lo svolgimento di
progetti di ricerca finanziati dall’AIRC e diretti alla definizione dei meccanismi di
upregolazione del recettore per il fattore di crescita epidermico (EGF-R) da parte
dell’interferone alfa.
Specialista in Oncologia
70/70 e lode
• Qualifica conseguita
• Livello nella classificazione
nazionale (se pertinente)
• Date (da – a)
• Nome e tipo di istituto di istruzione
o formazione
• Principali materie / abilità
professionali oggetto dello studio
• Qualifica conseguita
• Livello nella classificazione
nazionale (se pertinente)
• Date (da – a)
• Nome e tipo di istituto di istruzione
o formazione
Medicina Generale: Frequenza presso i reparti di Pediatria, Ginecologia ed Ostetricia e
Medicina Interna dell’Ospedale “S. Giovanni di Dio” di Frattamaggiore.
Abilitazione a Medico di Medicina Generale.
Non applicabile
1984-1990
Corso di Laurea in Medicina e Chirurgia della Facoltà di Medicina dell’Università
“Federico II” di Napoli.
Laurea in Medicina e Chirurgia. Frequenza presso il reparto di Oncologia ed il
laboratorio di Biologia Cellulare diretto dal Prof. P. Tagliaferri dell’allora Cattedra di
Oncologia della Facoltà di Medicina dal 1988 al 1990. Tesi di laurea sulla regolazione
dell’espressione dell’EGF-R da parte dell’interferone alfa in cellule di carcinoma
epidermoide umano in coltura.
Laurea in Medicina e Chirurgia
110/110 e lode con speciale menzione per la tesi
1979-1984
X Liceo Scientifico “Elio Vittorini” di Napoli
• Principali materie / abilità
professionali oggetto dello studio
• Qualifica conseguita
• Livello nella classificazione
nazionale (se pertinente)
Maturità Scientifica
Maturità Scientifica
60/60
CAPACITÀ E COMPETENZE
PERSONALI
.
MADRELINGUA
ITALIANO
ALTRE LINGUA
• Capacità di lettura
• Capacità di scrittura
• Capacità di espressione orale
CAPACITÀ E COMPETENZE
ARTISTICHE
INGLESE
Eccellente
Eccellente
Eccellente
SCRITTURA DI ELABORATI E TESTI PER LO STUDIO DELLA BIOCHIMICA E BIOCHIMICA CLINICA
PER STUDENTI DI LAUREE MAGISTRALI E TRENNALI.
Musica, scrittura, disegno ecc.
PATENTE O PATENTI
ULTERIORI INFORMAZIONI
Patente auto A e B.
Persone di riferimento:
Prof. Pierosandro Tagliaferri, Professore Ordinario di Oncologia presso l’Università
degli Studi “Magna Gaecia” di Catanzaro;
Prof. Simone Beninati, Professore Associato di Biologia della Università “Tor Vergata”
di Roma;
Prof. Giuseppe Tonini, Professore Associato di Oncologia, Università “Campus
Bio.Medico” di Roma.
Prof. Augusto Pessina, Professore Associato di Microbiologia, Università di Milano.
Prof. Marta Palmieri, Professore Ordinario di Biochimica, Università di Verona.
Prof. Maurizio Bifulco, Professore Ordinario di Patologia Generale della Università di
Salerno.
Prof. Roberta Tiozzo, Professore Ordinario di Patologia Generale della Università di
Modena e Reggio Emilia.
Curriculum Vitae
Dr. Pierpaolo Correale MD PhD
Name:
Pierpaolo Correale,
Date and place of birrth:
Dec, 8th, 1963, Naples, Italy
Citizenship:
Italian
Languages:
Italian and English
Education, work experience and expertise
Dr. Correale gained his Medical Degree at the “Federico II” University Medical School in Naples on July
25th, 1988 with the highest score.
At the same University, he also obtained his Doctorate in Experimental Oncology and his Clinical
Oncology Specialty with the highest score.
On August 1993, he became a guest researcher at the laboratory of Immunology, Biochemistry and
Immunopharmacology, National Institute of Allergy and Immune Disease, National Institute of Health
(NIH), Bethesda, MD, USA” under the supervision of Dr. Michail Sitkowsky. Subsequently, on August
1994, he started his Fogarty Fellowship at the “Laboratory of Tumour Immunology and Biology,
Experimental Oncology Section, National Cancer Institute (NCI), NIH, Bethesda, MD, USA”, directed by
Dr. Jeffrey Schlom under the supervision of Dr. K Y Tsang.
On March 1998, Dr. Correale was hired as a Medical Staff Member of the Medical Oncology Division at
the Siena University School of Medicine where, since September 1st, 2004, he was responsible for the
Translational Immune-Oncology Unit and Contract Professor in Oncology of either Medical School and
Medical Oncology Specialty Program.
On August 2012 he became Staff Member of the Radiotherapy Unit, Department of Oncology, at the
Siena University School of Medicine maintaining his responsibility concerning the Translational
Immune-Oncology Unit and Contract Professor in Oncology.
Dr Correale is a clinician with laboratory expertise in the field of cancer immunology, translational
oncology and clinical research on colon and lung cancer medical treatment.
He is the principal investigator and group leader involved in several preclinical and clinical projects.
He is co-author of four patents regarding peptide based cancer vaccines and immune-enhancers, and
author of a number of scientific manuscripts and congress presentation.
Sonia Quaratino, M.D., Ph.D. is Global Clinical Program Leader at Novartis. Trained at the University of
Palermo and Imperial College London, Dr Quaratino is a physician-scientist with a doctorate in hematology
and a PhD in Immunology from Imperial College, and was Professor in Immunology at the University of
Southampton. Her group worked on the basic mechanisms of T cell tolerance and activation involved in
inflammatory diseases, cancer and autoimmunity. She joined Merck-Serono from 2008-2014 as Senior
Medical Director and Advisor in Immunology , and lead immunotherapy programs in early and late stage of
development. In 2014 she joined Novartis Translational Clinical Oncology in Basel to develop early
immunotherapeutics
Dr. Kostas Kosmatopoulos, MD, PhD. Dr. Kosmatopoulos, Founder, is Chief Executive Officer and Chief
Scientific Officer of VAXON Biotech. Dr Kosmatopoulos was Research Director at INSERM and head of a laboratory
specializing in tumor immunotherapy in the Gustave Roussy Institute in Villejuif, France. Dr. Kosmatopoulos has coauthored more than 50 scientific and international publications. He received his medical degree at the University of
Thessaloniki, his medical oncology certification from Theagenion Cancer Research Institute, Greece, and his PhD in
Immunology (Doctorat d’Etat en Immunologie) at Paris XI University, France.
James L. Gulley, M.D., Ph.D., F.A.C.P.
Updated 10/31/14
DEMOGRAPHIC INFORMATION
Current Appointments
National Cancer Institute
2001-present Attending Physician, Center for Cancer Research, National Cancer Institute, National
Institutes of Health, Bethesda, MD
2011-present Director, Clinical Trials Group and Senior Investigator (Tenured), Laboratory of Tumor
Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of
Health, Bethesda, MD
2013-present Director, Medical Oncology Service, Center for Cancer Research, National Cancer Institute,
National Institutes of Health, Bethesda, MD
2013-present Chief, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer
Institute, National Institutes of Health, Bethesda, MD
Hospital
Senior Staff Member with Admitting Privileges, National Institutes of Health Clinical Center, National
Cancer Institute, National Institutes of Health, Bethesda, MD 20892 (credentialed since July 1998)
Staff Physician, Medical Oncology, National Naval Medical Center, Bethesda, MD 20889 (credentialed since
January 1999)
Staff Physician, Medical Oncology, Walter Reed Army Medical Center, Washington, DC 20307
(credentialed since December 2003)
Contact Information
Laboratory of Tumor Immunology and Biology
Center for Cancer Research
National Cancer Institute, National Institutes of Health
10 Center Dr., 12N226
Bethesda, MD 20892
Telephone: 301-435-2956
Fax: 301-480-5094
E-mail: gulleyj@mail.nih.gov
Education and Training
1983-1987
B.A. (Chemistry), Southern Adventist University, Collegedale, TN. Graduated
Magna Cum Laude and Southern Scholar
1987-1994
Ph.D. (Microbiology, research in tumor immunology), Loma Linda University, Loma
Linda, CA
1987-1995
M.D., Medical Scientist Training Program, Loma Linda University, Loma Linda, CA
1995-1998
Residency, Internal Medicine, Emory University, Atlanta, GA
1998-2000
Medical Oncology Fellowship, National Cancer Institute,
Bethesda, MD
2000-2001
Senior Clinical Fellow, Laboratory of Tumor Immunology and Biology, Center for
Cancer Research, National Cancer Institute, National Institutes of Health,
Bethesda, MD
Professional Experience
2001-2006
2006-2010
2010-2011
2011-2013
2011-present
2013-present
2013-present
Staff Clinician and Director, Clinical Immunotherapy Group, Laboratory of Tumor
Immunology and Biology, Medical Oncology Branch, Center for Cancer Research,
National Cancer Institute, National Institutes of Health, Bethesda, MD
Senior Clinician and Director, Clinical Trials Group, Laboratory of Tumor
Immunology and Biology, Center for Cancer Research, National Cancer Institute,
National Institutes of Health, Bethesda, MD
Tenure Track Investigator and Director, Clinical Trials Group, Laboratory of Tumor
Immunology and Biology, Center for Cancer Research, National Cancer Institute,
National Institutes of Health, Bethesda, MD
Deputy Chief, Laboratory of Tumor Immunology and Biology, Center for Cancer
Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
Senior (Tenured) Investigator and Director, Clinical Trials Group, Laboratory of
Tumor Immunology and Biology, Center for Cancer Research, National Cancer
Institute, National Institutes of Health, Bethesda, MD
Director, Medical Oncology Service, Center for Cancer Research, National Cancer
Institute, National Institutes of Health, Bethesda, MD
Chief, Genitourinary Malignancies Branch, Center for Cancer Research, National
Cancer Institute, National Institutes of Health, Bethesda, MD
Medical Licenses and Certifications
Medical license: State of Georgia, 1996 to 2007
Diplomate, National Board of Medical Examiners, 1996
Diplomate, Internal Medicine, American Board of Internal Medicine, 1999
Diplomate, Medical Oncology, American Board of Internal Medicine, 2000
Medical license: State of Maryland, 2001 to present
DEA registration # D0056966, 2001 to present
Advanced Cardiac Life Support, 1995 to 2007
Basic Cardiac Life Support, 1984 to present
Curriculum Vitae Alexander Helm
University Education
02/2010 - 07/2013
Technische Universität Darmstadt (Technical University Darmstadt,
Germany) Ph.D. Studies in Biology (Doctor rerum naturalium) Supervisor: Prof. Marco Durante
Ph.D. and Prof. Dr. Paul G. Layer
Thesis: Influence of High- and Low-LET Radiation on the Cardiac Differentiation of Mouse
Embryonic Stem Cells
Score: magna cum laude (“very good” in the German system)
10/2005 - 12/2009
Hochschule Darmstadt (University of Applied Sciences Darmstadt, Germany)
Graduate Engineer of Biotechnology Final Score: 1.5 ("very good" in the German system)
Thesis: Effects of Ions and X-rays on Human Endothelial Cells,
Score: 1.0
("very good" in the German system) Supervisor: Prof. Dr. Pollet and Dr. Sylvia Ritter
Working Experience
01/2016 – currently
05/2013 – 12/2015
11/2007 - 03/2009
03/2007 - 07/2007
Postdoc, TIFPA-INFN (Trento Institute for Fundamental Physics and
Applications), University of Trento, Trento, Italy
Postdoc, Biophysics Department, GSI Helmholtz Centre for Heavy
Ion Research, Darmstadt, Germany
Working student in research group of Prof. Dr. Dieter Pollet,
Department of Chemical Engineering and Biotechnology,
University of Applied Sciences Darmstadt, Germany
Internship, RCC Cytotest Cell Research GmbH, Rossdorf, Germany
Further Qualifications
Languages:
German (native), English (fluent), Italian (good), Spanish (good),
French (basic)
Courses:
NASA Space Radiation Summer School, May 28th – June 15th 2012,
Brookhaven National Laboratory, Upton, NY, USA
III. Course on Hadrons in Therapy and Space (International School of Heavy Ions), October 1st –
October 4th 2014, Erice, Sicily, Italy
LORENZO GALLUZZI, Ph.D.
galluzzi.lorenzo@aliceadsl.fr
deadoc@vodafone.it
Office:
Equipe 11, “Apoptose, cancer et immunité”
Centre de Recherche des Cordeliers de Jussieu
15, rue de l’École de Médecine
75006 Paris – FRANCE
Phone: +33-1-4427-7661
Mobile: +33-6-74251480
Fax: +33-1-4427-7681
Home – Permanent address:
v. D. Alighieri 227
41059 Zocca (Mo) – ITALY
Phone: +39-059-987383
Mobile: +39-3476936680
Home – Current address:
62-64, rue Nationale
75013 Paris – France
Phone: +33-9-51689338
ACADEMIC TITLES and HONORS:
Doctor of Philosophy, Cancerology, September 2008. Obtained with the Ph.D. Thesis entitled “TripleC – A
system biology study of apoptosis”.
Honors: Dissertation judged as “très honorable avec les félicitations du jury”
Master of Science, Medical Biotechnology, June 2004. Obtained with the dissertation “Quantitative analysis
of mitochondrial RNA by means of the real-time PCR: development of the technique and potential
applications”.
Honors: Dissertation passed “Summa Cum Laude”; Academic Career acknowledged with “Solemn
Encomium”
6th most-cited European cell biologist in 2017-2013 (1st Italian, 1st French and youngest) (source
http://www.labtimes.org/labtimes/ranking/2015_05/index.lasso)
Founding member of the European Research Institute for Integrated Cellular Pathology (ERI-ICP)
RESEARCH EXPERIENCE:
1. September 2001 – September 2002. Department of Biochemistry and Food Chemistry. University of
Turku, Turku – FINLAND. Laboratory of Dr. Matti Karp. Researcher.
2. February 2003 – December 2004. Department of Biomedical Sciences. Università degli Studi di Modena
e Reggio Emilia, Modena – ITALY. Laboratory of Dr. Andrea Cossarizza. Internist/Researcher.
3. January 2005 – August 2005. Department of Biochemistry and Food Chemistry. University of Turku,
Turku – FINLAND. Laboratory of Dr. Matti Karp. Research Assistant.
4. October 2005 – December 2011. INSERM – U848 “Apoptosis, cancer and immunity”. Institut Gustave
Roussy, Villejuif – FRANCE. Laboratory of Dr. Guido Kroemer. Ph.D. Student and Post-Doctoral Fellow.
5. January 2012 – Present. Université Paris Descartes “Apoptosis, cancer and immunity”. Centre de
Rechercher des Cordeliers, Paris – FRANCE. Laboratory of Dr. Guido Kroemer. “Immuno-Oncologie”
LabEx Manager.
Kwong Yok Tsang, Ph.D.
Senior Associate Scientist
Laboratory of Tumor Immunology and Biology
Head, Cellular Immunology Group
Dr. Tsang is a Senior Associate Scientist and Head of the Cellular Immunology Group in the Laboratory of Tumor
Immunology and Biology, NCI. He received his Ph.D. in microbiology from Bowling Green State University,
Bowling Green, OH. Dr. Tsang's research interests are in cellular immunotherapy; tumor immunology; cancer
vaccines; CTL epitopes. The Cellular Immunology Group studies the role of the human immune response to
tumor-associated antigens. We are working to define and develop immunodominant peptide epitopes and
modifications of these toward the optimal activation of human immune responses to tumor-associated antigens
(TAAs). Additionally, we are involved in studying mechanisms to enhance the potency of antigen-presenting cells
for specific Tcell activation and to decrease the suppressive effects of regulatory T-cells. We are also developing
immunologic methods and immunoassays to better define the patients' immune responses to vaccines, standard
of care therapy, and immune checkpoint inhibitors. The goals are to find suitable biomarkers for prediction of
response to immunotherapy and for monitoring of patients during and after immunotherapy. In addition, we are
investigating a monoclonal anti-PD-L1 antibody known to mediate ADCC.
John W. Greiner, Ph.D.
Staff Scientist
Laboratory of Tumor Immunology and Biology
Head, Cytokine Group
Dr. Greiner is a Staff Scientist and Head of the Cytokine Group in the Laboratory of Tumor Immunology and
Biology, NCI. He received his Ph.D. in Physiology and Biophysics from West Virginia University, Morgantown, WV.
Dr. Greiner's research interests are in cancer vaccines and immune adjuvants. The Cytokine Group studies the
interactions of cytokines and T cell checkpoint inhibitors on the different arms of the immune system to optimize
antitumor responses to recombinant vaccines and monoclonal antibody therapy. We are working to define novel
strategies for the delivery and use of cytokines and T cell checkpoint inhibitors as biologic adjuvants and
immunotherapeutics. Additionally, we are involved in the development of new animal models for the analysis of
new vaccines and vaccine strategies.
Curriculum Vitae Franchina Tindara
Cognome e nome
DOTT.SSA FRANCHINA TINDARA
MESSINA - ME- 17/07/1978
Luogo e data di nascita
Iscrizioni

07/03/2005 - Albo Provinciale dei Medici Chirurghi di MESSINA (Ordine
della Provincia di MESSINA) n. 0000008884
Lauree

21/07/2004 - MEDICINA E CHIRURGIA (MESSINA)
Abilitazioni

2004 /2 - Medicina e Chirurgia (MESSINA)
Specializzazioni

30/10/2008 - ONCOLOGIA (INDIRIZZO ONCOLOGIA MEDICA)
(MESSINA) - Specializzazione
Oncologa e Ricercatrice in Oncologia Medica Dipartimento di Patologia Umana - Università di Messina
PERSONAL INFORMATION
First name(s) / Surname(s)
Address
Telephone
Fax
E-mail
Nationality
Gender
Occupational field
Marianna Nuti
Dept. Experimental Medicine Viale Regina Elena 324, 00136 Rome Italy
office +39 06 4997-3029/ 3025
+ 39 06 4997 3029
marianna.nuti@uniroma1.it nutimarianna@gmail.com
Italian
Female
General Pathology MED 04
WORK EXPERIENCE
• Dates (from – to)
• Name and address of employer
• Type of business or sector
• Occupation or position held
• Main activities and responsibilities
2000-TODAY
University Sapienza Rome, Italy
University, Medical School
Full Professor Pathology
Teaching, Tutoring, Coordinator of III year Medical students
Scientific research, Laboratory Tumor Immunology , Director
Member of the Resource Committee of the Medical School Faculty
Appointed Member of the Scientific editorial board of Sapienza Press
Appointed Faculty Secretary (from 2001-2004)
Vicepresident elected of Nurse Academic programme (2000-2006)
Appointed Responsible of the Faculty Web Site
• Dates (from – to)
• Name and address of employer
• Type of business or sector
• Occupation or position held
• Main activities and responsibilities
2008-TODAY
Azienda Policlinico Umberto I Hospital
Hospital
Director, GMP Facility, Cell Therapy
Qualified Person for Human Cell Therapies GMP Facility
• Dates (from – to)
• Name and address of employer
• Type of business or sector
• Occupation or position held
• Main activities and responsibilities
1992-2000
University of Pisa, Italy
University, Medical School
Associate Professor Pathology
Teaching, Tutoring, Coordinator of III year Medical students
Scientific research, Laboratory Tumor Immunology , Director
• Dates (from – to)
• Name and address of employer
• Type of business or sector
• Occupation or position held
• Main activities and responsibilities
1982-1992
University of Pisa, Italy
University, Medical School
Research Associate Pathology
Teaching and Tutoring University Medical students
Scientific research, Laboratory Tumor Immunology
• Dates (from – to)
• Name and address of employer
• Type of business or sector
• Occupation or position held
• Main activities and responsibilities
1980-1982
National Cancer Institute, National Institutes of Health, Bethesda, Washington DC, USA
Medical Research
Post-Doc Fogarthy Fellow
Scientific research, Laboratory Tumor Immunology
• Dates (from – to)
• Name and address of employer
• Type of business or sector
• Occupation or position held
• Main activities and responsibilities
1979-80
University of Texas, MD Anderson Hospital, Houston Texas USA
University, Medical School
Fullbright Fellowship Scholar
Scientific research, Laboratory Tumor Immunology
EDUCATION AND TRAINING
• Dates (from – to)
• Name and type of organisation
providing education and training
• Principal subjects/occupational
skills covered
• Title of qualification awarded
1977-1978
University of Pisa
• Dates (from – to)
• Name and type of organisation
providing education and training
• Principal subjects/occupational
skills covered
1978-1979
Graduate School of Biomedical science
• Dates (from – to)
• Name and type of organisation providing
education and training
• Principal subjects/occupational
skills covered
• Title of qualification awarded
• Level in national classification
(if appropriate)
ORGANISATIONAL SKILLS
AND COMPETENCES
Biomedical Science
National Research Council Fellowship
Graduate Student in Biomedical science
1972-1976
University of Pisa
Biomedical science
Laurea in Scienze Biologiche
COORDINATOR OF SEVERAL NATIONAL AND INTERNATIONAL PROJECTS
DIRECTOR OF RESEARCH LABORATORY
LEADER OF SCIENTIC PROJECTS WITH ADMINISTRATIVE RESPONSIBILITY
APPOINTED FOR COORDINATION OF ACADEMIC ORGANIZATION ( STUDENTS MANAGEMENT, FACULTY WEB SITE, FACULTY
ORGANIZATION)
MOTHER TONGUE
ITALIAN
OTHER LANGUAGES
• Reading skills
• Writing skills
• Verbal skills
ENGLISH
excellent
excellent
excellent
• Reading skills
• Writing skills
• Verbal skills
FRENCH
basic
basic
good
Elodia Martino : Dottore Magistrale in Biologia Molecolare presso l’Azienda Ospedaliera Universitaria Senese - Siena, Italia - Ricerca
Attuale
Azienda Ospedaliera Universitaria Senese
Formazione1. Università degli Studi di Siena
Esperienza
Dottore Magistrale in Biologia Molecolare
Azienda Ospedaliera Universitaria Senese
settembre 2013 – Presente (2 anni 7 mesi)
Borsista
Azienda Ospedaliera Universitaria Senese
settembre 2013 – Presente (2 anni 7 mesi)
Formazione:
Università degli Studi di Siena
Laurea magistrale in biologia cellulare e molecolare, facoltà di SMFN
Francesca Vanni:
Esperienza
Dottore Magistrale in Biologia Molecolare
Azienda Ospedaliera Universitaria Senese
settembre 2013 – Presente (2 anni 7 mesi)
Borsista
Azienda Ospedaliera Universitaria Senese
settembre 2013 – Presente (2 anni 7 mesi)
Formazione:
Università degli Studi di Siena
Laurea magistrale in biologia cellulare e molecolare, facoltà di SMFN
Takuya Tsunoda, M.D.,Ph.D
Visiting lecture, Wakayama School of Medicine, Department of Surgery
Head of Medical Affairs Oncology, Merck Serono Japan